Mr. Jacks has spent 18 years in the biopharmaceutical industry focused on product development, corporate strategy, business development, fund raising, commercial analysis, finance, and operations. Most recently, Mr. Jacks was the President, CFO, and Co-Founder of Symbiomix Therapeutics, a venture-backed company that was sold to Lupin Pharmaceuticals, Inc., in 2017 after achieving NDA approval for Solosec®. Prior to Symbiomix, Mr. Jacks worked for several private biotechnology firms, including Tobira Therapeutics as Head of Corporate Development and ACT Biotech as Head of Business Development. Mr. Jacks also previously worked as an Entrepreneur-in-Residence for OrbiMed and as a Director of Business Development for Pfizer, where he led the Licensing Leadership Teams for Oncology and Infectious Diseases. Mr. Jacks received an M.B.A. from Columbia Business School, an M.S.E. in Civil Engineering from Stanford University, and a B.S.E. in Civil Engineering from Duke University.